Study halted: Long-Term safety of rare blood disorder drug under scrutiny
NCT ID NCT04802057
Summary
This study aimed to check the long-term safety and side effects of an investigational drug called SAR445088 in adults with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. It planned to follow a small group of participants for up to two years to see how their bodies handled the drug over time. The study was terminated early, and its development was discontinued.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HAEMOLYTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 2760001
Essen, 45147, Germany
-
Investigational Site Number : 3800001
Milan, Milano, 20122, Italy
-
Investigational Site Number : 5280001
Amsterdam, 1081 HV, Netherlands
-
Investigational Site Number : 5780001
Bergen, 5021, Norway
-
Investigational Site Number : 8260001
London, London, City of, NW1 2PG, United Kingdom
Conditions
Explore the condition pages connected to this study.